Clinical Trial Update: A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 safety study of EPC2407, a vascular-disrupting anti-cancer agent, in patients with advanced cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• EPC2407

Snippet

Sponsor: EpiCept Corporation | Conditions: Advanced Cancer | Phase 1 | Status: COMPLETED